Difficulties in achieving a reduction in morbidity and mortality in patients with diabetes are a result of the complexity of the disease and its intertwined relationship with hypertension and renal impairment. In the recently published Action in Diabetes and Vascular disease: PreterAx and DiamicroN-MR Controlled Evaluation (ADVANCE) trial, treatment of patients with diabetes with the fixed combination perindopril/indapamide on top of background treatments provided clinically and statistically significant reductions in blood pressure (from 145/81 to 136/73 mmHg), all-cause mortality (S14%), cardiovascular mortality (S18%), major cardiovascular events (S9%), renal events (S21%) and new-onset microalbuminuria (S21%) when compared with placebo. As the ADVANCE trial included both hypertensive and normotensive patients, its results suggest that systematically treating all patients with diabetes with perindopril/indapamide, independently of their baseline blood pressure, may have significant longterm value that can be explained partly by the reversal of end-organ damage to the kidney and the heart. Considering that patients with both hypertension and diabetes are characterized by generalized macro-and microvascular disease, the results of the ADVANCE trial, taken together with results of other perindopril/indapamide hypertension studies, support a broad use of perindopril/indapamide treatment for the long-term improvement of prognosis in hypertensive patients as well as in patients with diabetes. © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.

Mancia, G., Grassi, G. (2009). Protection of patients with diabetes, with or without hypertension: Implications of ADVANCE for clinical practice. JOURNAL OF HYPERTENSION, 27(Suppl. 1), S19-S23 [10.1097/01.hjh.0000354420.23557.e2].

Protection of patients with diabetes, with or without hypertension: Implications of ADVANCE for clinical practice

MANCIA, GIUSEPPE;GRASSI, GUIDO
2009

Abstract

Difficulties in achieving a reduction in morbidity and mortality in patients with diabetes are a result of the complexity of the disease and its intertwined relationship with hypertension and renal impairment. In the recently published Action in Diabetes and Vascular disease: PreterAx and DiamicroN-MR Controlled Evaluation (ADVANCE) trial, treatment of patients with diabetes with the fixed combination perindopril/indapamide on top of background treatments provided clinically and statistically significant reductions in blood pressure (from 145/81 to 136/73 mmHg), all-cause mortality (S14%), cardiovascular mortality (S18%), major cardiovascular events (S9%), renal events (S21%) and new-onset microalbuminuria (S21%) when compared with placebo. As the ADVANCE trial included both hypertensive and normotensive patients, its results suggest that systematically treating all patients with diabetes with perindopril/indapamide, independently of their baseline blood pressure, may have significant longterm value that can be explained partly by the reversal of end-organ damage to the kidney and the heart. Considering that patients with both hypertension and diabetes are characterized by generalized macro-and microvascular disease, the results of the ADVANCE trial, taken together with results of other perindopril/indapamide hypertension studies, support a broad use of perindopril/indapamide treatment for the long-term improvement of prognosis in hypertensive patients as well as in patients with diabetes. © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Articolo in rivista - Articolo scientifico
Diabetes; Hypertension; clinical study; therapy and prevention.
English
2009
27
Suppl. 1
S19
S23
none
Mancia, G., Grassi, G. (2009). Protection of patients with diabetes, with or without hypertension: Implications of ADVANCE for clinical practice. JOURNAL OF HYPERTENSION, 27(Suppl. 1), S19-S23 [10.1097/01.hjh.0000354420.23557.e2].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/10143
Citazioni
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 15
Social impact